Compare GOAI & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOAI | TENX |
|---|---|---|
| Founded | 2015 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 74.1M |
| IPO Year | 2023 | 2001 |
| Metric | GOAI | TENX |
|---|---|---|
| Price | $1.55 | $1.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.56 |
| AVG Volume (30 Days) | 111.5K | ★ 2.1M |
| Earning Date | 11-08-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 966.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,037,328.00 | N/A |
| Revenue This Year | $14.45 | N/A |
| Revenue Next Year | $53.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.59 | N/A |
| 52 Week Low | $1.42 | $1.31 |
| 52 Week High | $6.67 | $19.40 |
| Indicator | GOAI | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 36.08 | 28.75 |
| Support Level | $1.42 | $1.31 |
| Resistance Level | $2.66 | $2.00 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 10.21 | 20.31 |
Eva Live Inc is a United States-based technology company that has developed an automated and intelligent advertiser campaign management platform, Eva Platform, which enables advertisers ('customers, clients') to buy advertising space on several digital channels to reach their desired audience. The company also works with Businesses that utilize its in-house digital marketing capabilities, including advice, creative services, account management, production of advertising materials, media planning, and buying.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.